will continue to evolve MyAir based on consumer and provider feedback. Our aim is to bring clearer therapy insights, to bring more intuitive support, and to bring increasingly personalized experience to engage patients throughout their therapy journey. Together with AirView, ResMed's remote monitoring platform for healthcare providers, MyAir has been shown to meaningfully improve therapy compliance from 70% up to 87%, just by adding MyAir for the patient. One further update regarding our FDA cleared AI enabled digital medical device that we call Smart Comfort. We launched this just earlier this calendar year. Smart Comfort was built on millions and millions of nights of ResMed sleep data to recommend personalized adjustments to comfort settings like temperature, humidity, and it's and it's applied on new AirSense 11 users. We predicted in previous quarters that increased comfort could lead to increased adherence. And it turns out that prediction has come true. Early real-world data shows a 4.3% increase in 30-day compliance versus the device's default settings. Smart Comfort has been selected as a special mention in Time magazine's best inventions of 2026. But it more important than that, it's evolving our products to deliver increasingly personalized therapy to patients, and it's a winning use case for AI. Resmed's digital health ecosystem is second to none, providing sustainable value for patients, for physicians, for providers, even for payers and beyond. ? On the operational excellence side, we were able to execute some of our planned supply chain initiatives more quickly than we'd predicted. We're able to rephase some of our planned expansion initiatives, particularly in Indianapolis, Indiana, allowing us to exceed our own expectations for gross margin for the quarter. The transformational pipeline of initiatives, what I call our productivity pipeline for our supply chain team, they built it and it remains robust and multi year, underpinning our ongoing confidence that we can deliver double digit basis points improvements in gross margin every year, every fiscal year through 2030. I'm also proud to share that we've produced our first made in America CPAP device, an Essence 11, has come off the line at our Atlanta, Georgia facility. Having this capability for U.S. manufacturing gives ResMed additional flexibility to optimize operations as needed across our global manufacturing footprint. We also continue progress on our new Indiana Indianapolis based distribution center, which, once it's fully operational, will enable faster delivery to our North American customers. Resmed has a significant and growing U.S. manufacturing presence, and we continue to invest in expanding our capability to serve our highest volume market. With regard to our government advocacy work, I can tell you that we are actively engaged with the U.S. government as well as industry partners to support policies that strengthen domestic U.S. manufacturing and global supply chain resilience, while protecting patient access to our life saving therapy in the US and around 144 countries worldwide. Alongside these developments in the US, we are expanding our Asia manufacturing capabilities, including at our largest manufacturing facility in Singapore, and our facilities in Malaysia that are joined to the Singapore operation. Together with our Sydney, Australia, Calabasas, California, Atlanta, Georgia, and our newly established Indianapolis, Indiana facilities, our global operations footprint positions us extremely well to serve our growing customer base and patients around the world. Over the past quarters, I've highlighted our initiatives to increase awareness of sleep apnea and the impact that chronic poor sleep has both on the individuals and healthcare system, but also on their partners and families and workmates. As you know, we've been excited to see growing appreciation of the importance of sleep health, driven by consumer wearables, including Samsung Galaxy Ring, that just this week, I think actually overnight, uh got FDA clearance for sleep apnea detection from their Samsung Galaxy Ring. But also from Big Pharma ? and the GLP1s, the investment that particularly Lily is making, but also Nova and driving patients into primary ? care. Earlier this month, we announced a collaboration with Smart Mattress sensor maker 8Sleep. Their Eight Sleep Pod users in both the US and Australia markets will be able to securely connect their MyAir Sleep Insights to the ATSleep app, giving them a more complete picture of their sleep health. Here in Australia, ATSleep users whose sleep data shows trends such as heavy snoring may be guided to ResMed's sleep health resources, including sleep assessments and the pathway to diagnosis and therapy and beyond. This consumer sleep wellness collaboration adds to our partnership with Smart RingMaker Aura that I discussed during ResMed's last earnings call. We've continued to see strong traffic to Resmed's website from Aura app users. As of September 30, approximately 28,000 Aura users, more than double what we had seen at the end of July, have come to resmed.com from a customized tile within Aura's own app. Many thousands of those users have taken the ResMed sleep assessment right there on Resmed.com. Approximately 72% of those assessed identified themselves as previously undiagnosed for OSA, highlighting the potential to turn sleep insights into action and helping more people get evaluated and ultimately treated for their sleep apnea. Another sleep pathway enabler are these new medicines, well, not so new, maybe 10-15 years in the market, but newly ramping up GLP1s. As we've discussed before, patients on GLP1s both initiate CPAP therapy more and stay on CPAP therapy longer, and they buy more stuff. ? As an update to our analysis that's built from a claims database of tens of millions of patients, our specifically analyzed cohort now includes more than 3.3 million de-identified patients. We are still seeing that patients who have scripts for both CPAP and GLP1s are more than 11% more likely to start on CPAP therapy than patients who have a script for CPAP alone. They are also more than 3% more likely to have a resupply event at one year and more than 7% more likely to have a resupply event at three years. The CPAP plus GLP1 and the CPAP only cohorts are measured on the same basis, i.e., patients who stop CPAP remain in the base population for both groups. Sleep apnea risk factors include age, gender, craniofacial geometry, as well as weight. OSA very often needs to be treated even after very significant weight loss, as we've seen in the clinical literature, the real-world data that we show, and in the numbers if you look at our incredible mass growth over time. Resmond continues to selectively invest in marketing that expands our awareness, reduces barriers to diagnosis and treatment, and helps more people understand the life-changing impact of better sleep, better breathing. You may have seen some of our campaigns underway. I'll highlight just three of them quickly here on our call. Number one, our so-called CPAP baddies campaign is helping normalize CPAP therapy through authentic community-driven conversations, making treatment more approachable and encouraging more people to start and say stay on therapy. It's really creating a CPAP community of people who are proud of changing their lives. Number two, our In Bed With interview series features sleep doctors, sleep physicians, and other sleep wellness thought leaders to help more people recognize symptoms of sleep apnea, to seek care, and ultimately to improve long term clinical outcomes as well as quality of life outcomes. And thirdly, and finally, our athletic partnerships, most recently with a NASCAR driver Tyler Reddick, enable us to reach new audiences with powerful real world stories that demonstrate how effective sleep therapy can improve energy, performance, and personal and family life. It's interesting. The most watched episode featuring Tyler Reddick, who's a world-class professional driver, was not about his improvement in sports performance and winning the Daytona 500 in the first three NASCAR races of the season, creating new sports records for that sport. The most watched podcast and viral social media was about his wife, Alexa, sharing that Resmed CPAP treatment made him a better husband, a better father, and a better friend. The words from patient one back here in Australia in 1989, Eddie Merck, who said, This therapy saved my marriage, saved my job, saved my life, come to mind. It's great to have that story retold from many perspectives and from a young race car driver here right in 2026. Okay, together these sort of consumer engagement initiatives are helping ResMed interact with more people, driving greater awareness and adoption. And ultimately, they fulfill our mission of improving lives through better sleep and better breathing, longer life, which is longevity, lifespan, but more importantly, health span, which is living longer with a good quality of life. Greater awareness in the clinical community is another key element to ensuring consumers have ready access to information and pathways to diagnosis and therapy. Our continuing medical education or CME programs include sleep medicine physician society approved guidelines. Obviously, that includes the benefits of CPAP, APAP, and Bilevel Therapy as the clinical gold standard, the frontline treatment for any patient diagnosed with sleep apnea. ? Our sleep apnea education courses have now been completed by approximately 108,000 times by more than 63,000 unique clinicians. We've been tracking the number of referrals for home sleep apnea tests and prescriptions for positive airway pressure both before and after training. It's great to see that post-training, these clinicians are not only saying they intend to change their clinical practices, they are actually changing them and it's impacting patient flow. Okay, our second priority is active portfolio management. On September 1st, we closed on the divestiture of our matrix care business. We continue to expect this move to accelerate the growth and profitability of our core residential care or RCS business. For fiscal year 2027, we are still planning for our RCS business to deliver high single digit revenue growth with operating leverage reflecting both improved mix and execution focus. We're off to a solid start with high single digit growth powered by our Bright Tree and Medifox Darn product lines. We're also making good early progress integrating our NEEDRA or Restless Legs Syndrome Therapy that we acquired with a company that was called Noctrix from the Stanford's Biodesign Incubator. NIDRA's commercial footprint is expanding rapidly, albeit from a small base. We're keenly focused on increasing commercial coverage for NIDRA and supporting expanded access to this novel, non invasive, sleep physician prescribed, DME channel delivered, VA channel delivered to patients therapy. Prioritizing patient care is also central to our ongoing astral field safety corrective action. We're responsibly supporting patients, including patient-centric and quality-focused completion of the ongoing action. We also recognize that home care provider customers need to be able to plan for future ventilation needs. That commitment is why we recently announced that we will no longer sell the astral device. We're focusing all available components to service astral devices for existing patients, with prioritization based on the highest clinical acuity and guided by clinical judgment. We're going to execute the best recall in the history of life support ventilation. We took $42 million reserve, and I've seen the latest data, and it's very good. We're executing very well in that field safety notice. We intend to keep allocating capital towards our high growth, high return opportunities. This allows us to accelerate the expansion of our digital health ecosystem to support continued innovation at scale and to drive strong progress towards successful execution of our 2030 strategy. Excuse
Passages & reports (49) 7:09 will continue to evolve MyAir based on consumer and provider feedback. Our aim is to bring… Report 7:29 platform for healthcare providers, MyAir has been shown to meaningfully improve therapy co… Report 7:48 Comfort. We launched this just earlier this calendar year. Smart Comfort was built on mill… Report 8:08 predicted in previous quarters that increased comfort could lead to increased adherence. A… Report 8:28 a special mention in Time magazine's best inventions of 2026. But it more important than t… Report 8:47 physicians, for providers, even for payers and beyond. Report 8:53 On Report 8:53 the operational excellence side, we were able to execute some of our planned supply chain … Report 9:13 initiatives, what I call our productivity pipeline for our supply chain team, they built i… Report 9:33 that we've produced our first made in America CPAP device, an Essence 11, has come off the… Report 9:53 also continue progress on our new Indiana Indianapolis based distribution center, which, o… Report 10:13 serve our highest volume market. With regard to our government advocacy work, I can tell y… Report 10:32 and around 144 countries worldwide. Alongside these developments in the US, we are expandi… Report 10:52 Atlanta, Georgia, and our newly established Indianapolis, Indiana facilities, our global o… Report 11:11 that chronic poor sleep has both on the individuals and healthcare system, but also on the… Report 11:31 got FDA clearance for sleep apnea detection from their Samsung Galaxy Ring. But also from … Report 11:38 and Report 11:38 the GLP1s, the investment that particularly Lily is making, but also Nova and driving pati… Report 11:44 care. Report 11:45 Earlier this month, we announced a collaboration with Smart Mattress sensor maker 8Sleep. … Report 12:05 of their sleep health. Here in Australia, ATSleep users whose sleep data shows trends such… Report 12:24 collaboration adds to our partnership with Smart RingMaker Aura that I discussed during Re… Report 12:44 July, have come to resmed.com from a customized tile within Aura's own app. Many thousands… Report 13:04 undiagnosed for OSA, highlighting the potential to turn sleep insights into action and hel… Report 13:24 ramping up GLP1s. As we've discussed before, patients on GLP1s both initiate CPAP therapy … Report 13:38 As Report 13:38 an update to our analysis that's built from a claims database of tens of millions of patie… Report 13:58 on CPAP therapy than patients who have a script for CPAP alone. They are also more than 3%… Report 14:18 measured on the same basis, i.e., patients who stop CPAP remain in the base population for… Report 14:38 as we've seen in the clinical literature, the real-world data that we show, and in the num… Report 14:58 sleep, better breathing. You may have seen some of our campaigns underway. I'll highlight … Report 15:17 encouraging more people to start and say stay on therapy. It's really creating a CPAP comm… Report 15:37 symptoms of sleep apnea, to seek care, and ultimately to improve long term clinical outcom… Report 15:57 demonstrate how effective sleep therapy can improve energy, performance, and personal and … Report 16:16 season, creating new sports records for that sport. The most watched podcast and viral soc… Report 16:36 1989, Eddie Merck, who said, This therapy saved my marriage, saved my job, saved my life, … Report 16:56 interact with more people, driving greater awareness and adoption. And ultimately, they fu… Report 17:16 to ensuring consumers have ready access to information and pathways to diagnosis and thera… Report 17:36 frontline treatment for any patient diagnosed with sleep apnea. Report 17:39 Our Report 17:40 sleep apnea education courses have now been completed by approximately 108,000 times by mo… Report 18:00 It's great to see that post-training, these clinicians are not only saying they intend to … Report 18:20 to expect this move to accelerate the growth and profitability of our core residential car… Report 18:40 focus. We're off to a solid start with high single digit growth powered by our Bright Tree… Report 19:00 the Stanford's Biodesign Incubator. NIDRA's commercial footprint is expanding rapidly, alb… Report 19:19 VA channel delivered to patients therapy. Prioritizing patient care is also central to our… Report 19:39 ventilation needs. That commitment is why we recently announced that we will no longer sel… Report 19:59 life support ventilation. We took $42 million reserve, and I've seen the latest data, and … Report 20:17 innovation at scale and to drive strong progress towards successful execution of our 2030 … Report